TSC2 and renal cell carcinoma: MRD cells were also generated in vivo, by treating mouse xenografts of the 105K Tsc2–/– RCC line in syngeneic C57BL/6J mice with rapamycin (3 mg/kg, intraperitoneally [IP] 3 times/wk for 1 month, MRD525), or the bi-steric inhibitor RMC-6272 (8 mg/kg, IP once/wk for 1 month, MRD639), followed by 2 months of treatment cessation (Figure 1A).